AI assistant
Sending…
UroGen Pharma Ltd. — Director's Dealing 2024
Feb 5, 2024
32312_dirs_2024-02-05_f9bedc59-cda9-4fe5-be2d-a890cbfb5fac.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2024-01-31
Reporting Person: Schoenberg Mark (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-01 | Ordinary Shares | S | 1137 | $15.78 | Disposed | 149423 | Direct |
| 2024-02-01 | Ordinary Shares | S | 758 | $15.78 | Disposed | 149998 | Direct |
| 2024-02-01 | Ordinary Shares | S | 1894 | $15.78 | Disposed | 151437 | Direct |
Footnotes
F1: This amendment corrects and restates the date of sale reported in the original Form 4 filed on February 2, 2024.
F2: This amendment corrects and restates the sales price reported in the original Form 4 filed on February 2, 2024.
More from UroGen Pharma Ltd.
Annual Report
2026
May 27
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 30
Annual Report
2026
Mar 2
Regulatory Filings
2026
Mar 2
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 11